WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > eHealth Initiative
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Pharma Tech
PRNewswire | June 19, 2023
ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialization. Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network. Monitoring the brain's field potential an...
Business Insights
Juno Pharmaceuticals | February 25, 2022
Juno Pharmaceuticals Corp a Canadian specialty generics pharmaceuticals company, announced that it has received a strategic growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare growth equity firm. Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio and to accelerate growth. “We are very pleased with the opportunity to partner with the Juno management te...
Research
Nanoform | March 23, 2021
Nanoform innovative nanoparticle medicine enabling company next generation of its STARMAP® AI artificial intelligence platform nanoparticle bioavailability excipient microns nm CESS technology silico pharma drugs lifecycle managementNanoform, an innovative nanoparticle medicine enabling company, has today dispatched the next generation of its STARMAP® AI (artificial intelligence) platform, v2.0. The technology uses scanty information AI to expand trial results from its CESS® nanopart...
Titan Pharmaceuticals, Inc. | February 03, 2022
Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE